Oncology Peer Review On-The-Go: 1-on-1 with Dr. Michael Randell: New ACS Guidelines for Cervical Cancer

Podcast

The latest episode of Oncology Peer Review On-The-Go sits down with Michael D. Randell, MD, FACOG, to discuss the latest updates to cervical cancer screening guidelines by the American Cancer Society.

In this week’s episode of “Oncology Peer Review On-The-Go,” CancerNetworkspeaks with Michael D. Randell, MD, FACOG, of OBGYN Atlanta, to learn more about the new cervical cancer screening guidelines released by the American Cancer Society. In the interview, Randell expresses his concerns with the updated guidelines, and details what he recommends to patients.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

Recent Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.
Related Content
Pioneering Progress in Gynecologic Oncology: A Career of Many Advancements

Pioneering Progress in Gynecologic Oncology: A Career of Many Advancements

Ariana Pelosci
February 24th 2025
Article

As a gynecologic oncology surgeon, Mario M. Leitao, MD, FACOG, FACS, highlights how his career has evolved through using robotic surgery, new fertility preservation techniques, and his contributions to the research field.

The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.

Jyoti S. Mayadev, MD, on Pembrolizumab/CRT FDA Approval in Cervical Cancer

Jyoti Mayadev, MD
January 22nd 2024
Podcast

The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.

Results from the phase 3 KEYNOTE-826 trial show that the safety profile of pembrolizumab plus chemotherapy was manageable in cervical cancer.

Pembrolizumab Plus Chemotherapy Improves OS, PFS in Cervical Cancer

Roman Fabbricatore
December 17th 2024
Article

Results from the phase 3 KEYNOTE-826 trial show that the safety profile of pembrolizumab plus chemotherapy was manageable in cervical cancer.

Julianne Cooley, MS, spoke with CancerNetwork® about older patients with later stage cervical cancer who have lower survival rates compared with their younger counterparts.

Oncology Peer Review On-The-Go Podcast: Cervical Cancer Screenings/Survival in Those 65+ Years

Julianne Cooley, MS
February 2nd 2023
Podcast

Julianne Cooley, MS, spoke with CancerNetwork® about older patients with later stage cervical cancer who have lower survival rates compared with their younger counterparts.

Subgroup data indicate a positive efficacy trend for TG4001 plus avelumab among patients with cervical cancer.

Cancer Vaccine Combo Does Not Improve PFS in Cervical/Anogenital Tumors

Russ Conroy
October 15th 2024
Article

Subgroup data indicate a positive efficacy trend for TG4001 plus avelumab among patients with cervical cancer.

Expert Commentary on the Product Profile of Tisotumab Vedotin in Cervical Cancer

Expert Commentary on the Product Profile of Tisotumab Vedotin in Cervical Cancer

Laura Bucher-Bailey, PharmD
September 25th 2024
Article

Laura Bucher-Bailey, PharmD, discussed the approval of tisotumab vedotin-tftv for patients with recurrent or metastatic cervical cancer who have had progression after chemotherapy.